DOK2 inhibits EGFR-mutated lung adenocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Somatic mutations in the Epidermal Growth Factor Receptor (EGFR) proto-oncogene are prevalent in lung adenocarcinomas.
• EGFR mutations are critical drivers for lung cancer initiation and progression.
• DOK2 has been recently identified as a potential tumor suppressor gene in lung adenocarcinoma.

Purpose of the Study:

• To investigate the association between DOK2 loss and EGFR mutations in human lung adenocarcinoma.
• To determine if DOK2 loss cooperates with EGFR mutations in promoting lung tumorigenesis.
• To elucidate the mechanism by which DOK2 loss impacts EGFR-mutant lung cancer.

Main Methods:

• Analysis of genomic DOK2 loss in human lung adenocarcinoma samples.
• Utilizing genetically engineered mouse models to test the hypothesis in vivo.
• Investigating the molecular interaction between DOK2 and mutated EGFR signaling pathways.

Main Results:

• Genomic loss of DOK2 is significantly associated with EGFR mutations in human lung adenocarcinoma.
• Loss of DOK2 accelerates lung tumorigenesis driven by oncogenic EGFR in mouse models.
• Loss of DOK2 does not accelerate lung tumorigenesis initiated by mutated KRAS.
• DOK2 negatively regulates mutated EGFR signaling by inhibiting RAS activation.
• EGFR mutation leads to DOK2 recruitment to EGFR, mediating inhibition of RAS pathway.

Conclusions:

• DOK2 functions as a tumor suppressor in the context of EGFR-mutant lung adenocarcinoma.
• Loss of DOK2 cooperates with EGFR mutations to promote lung tumorigenesis.
• DOK2 plays a crucial role in a negative feedback loop opposing mutated EGFR signaling.